

# ForPatients

by Roche

Nasal Polyps

## An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps

**Trial Status**  
Completed

**Trial Runs In**  
14 Countries

**Trial Identifier**  
NCT03478930 2017-003450-16  
WA40169

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### ***Trial Summary:***

The overall purpose of this study is to evaluate the safety, efficacy, and durability of response of omalizumab in an open-label setting in adult participants with chronic rhinosinusitis with nasal polyps who completed the double-blind, placebo-controlled, Phase III studies GA39688 (NCT03280550) or GA39855 (NCT03280537). Participants will be eligible for enrollment in the study at, or within 28 days after, the Week 24 visit of Studies GA39688/GA39855. After enrollment into this open-label extension (OLE) study, participants will receive 28 weeks of dosing of omalizumab before entering a 24-week off-treatment observation phase of the study. Baseline in this OLE study is defined as the last pre-treatment measurement prior to randomization in Studies GA39688/GA39855 (i.e., baseline of Studies GA39688/GA39855). The data that will be reported from baseline to Week 24 inclusive will come from Studies GA39688/GA39855.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT03478930 2017-003450-16 WA40169**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>= 18 Years & <= 75 Years

**Healthy Volunteers**  
No

---